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ABSTRACT
Introduction: Huntington’s disease (HD) is an autosomal dominant, neurodegenerative disorder.
Despite the severe motor, psychiatric and cognitive symptoms and the great socioeconomic burden
10 caused by the disease, available treatment is mainly symptomatic.
The kynurenine pathway (KP) is the main metabolic route of tryptophan degradation, in the course
of which several neuroactive compounds are generated. The imbalance of the neurotoxic and neuro-
protectant metabolites can lead to excitotoxicity and overproduction of reactive oxygen species, which
both contribute to the progression of HD. Indoleamine 2,3-dioxygenase 1 (IDO1) is a key enzyme of the
15 KP that has various immune modulatory roles.
Areas covered: Current knowledge of the involvement of KP in HD pathogenesis with a particular focus
on IDO1. By reviewing the diverse roles of the enzyme in kynurenine production, immune modulation,
and serotonin metabolism, we elucidate the factors that make this enzyme a therapeutic target.
Expert opinion: Due to the complexity of HD and the various effects that IDO1 exerts, targeting this
20 enzyme, while highly profitable, may be a great challenge. Through IDO1 activity, neurodegeneration,
inflammatory processes and depressive symptoms, often related to HD, can be modulated. Ongoing
trials of IDO1 inhibitors in other areas of medicine offer advantages for initiating approaches toward this
enzyme as a therapeutic target.
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1. Introduction
25 Huntington’s disease (HD) is a hereditary, autosomal domi-
nant, progressive neurodegenerative disease with various
motor, psychiatric and cognitive symptoms (for a review see
[1]), that affects 6–13 individuals out of 100,000 [2]. Despite
the severity of the disease, available therapy for HD is mainly
30 symptomatic.
The kynurenine pathway (KP) is the main route of trypto-
phan (Trp) metabolism with several metabolites that have
been identified to be neuroactive. As imbalances of neuropro-
tectant and neurotoxic metabolites have been proposed to be
35 key factors in HD, elements of the KP might offer potential
therapeutic targets for the disease.
In this review, we will consider indoleamine 2,3-dioxygen-
ase (IDO), the first and rate-limiting enzyme of the KP, as
a novel therapeutic target for HD treatment. The modulation
40 of IDO activity provides opportunity for restoring the balance
between neuroprotectant and neurotoxic metabolites of the
KP and, due to the diverse functions of IDO in immune regula-
tion, it also offers possible ways to interfere with altered
inflammatory processes in HD.
45 Here we summarize the available data on KP alterations
that are related to HD, with particular attention to IDO. We
would like to emphasize that due to the diverse effects of IDO
functions and the complexity of HD pathogenesis, there are
several junctions between HD and KP, that make IDO
50a potential therapeutic target for HD treatment. In order to
explore these possibilities, we will outline the pathological
mechanisms underlying HD and summarize available data on
KP alterations in the disease.
1.1. A brief overview of Huntington’s disease
55pathogenesis
The genetic background of HD was elucidated in 1993 with
the identification of an expansion of CAG trinucleotide repeats
in exon 1 of the Huntingtin (HTT) gene [3]. The trinucleotide
repeat expansion leads to the formation of an elongated
60polyglutamine sequence (polyQ) at the N terminal region of
Huntingtin protein (HTT) [3]. Although HTT has been shown to
interact with a large number of various proteins, among them
components of the cytoskeleton and plasma membrane,
synaptic vesicles and transcriptional factors [4], its detailed
65physiological function is still unknown. Due to the presence
of an elongated polyQ sequence (over 35 Glu), the mutant
protein becomes insoluble and forms aggregates, both in the
cytoplasm and in the nucleus [5]. It seems that the HTT protein
with extended polyQ is toxic to neurons [6], and an increasing
70body of evidence suggest that the formation of inclusion
bodies is a coping mechanism of the cells against the mutant
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HTT protein and not an early sign of cell death [7]. Cells with
inclusion bodies survive longer than those [8].
Neurodegeneration in HD is most prominent in the striatum,
75 mainly due to the selective loss of the GABAerg medium spiny
neurons (MSNs) [9]. These neurons receive glutamatergic and
dopaminergic inputs from the cortex and substantia nigra,
respectively, and also from striatal interneurons [10], and pro-
ject to several components of the basal ganglia (for a review
80 see [11]). MSNs express various receptors of which the
N-methyl-D-aspartate (NMDA) glutamate receptor seems to
have a cardinal role in the development of HD [12].
Several cellular pathomechanisms have been identified to
contribute to the development and progression of the disease
85 (for a review see [13]). These involve excitotoxicity, mitochon-
drial dysfunction, and associated impairment in energy meta-
bolism, excessive production of reactive oxygen species (ROS),
lipid, and protein oxidation. Whether these pathological
mechanisms are causes or effects of each other cannot be
90 clearly distinguished as these processes are tightly connected
and their malfunctions lead to a vicious circle.
The occurrence of excitotoxicity (which refers to neuronal
death due to the activation of amino acid receptors [14]) in HD
pathogenesis was initially proposed based on observations by
95 Coyle and Schwarcz that the injection of kainic acid (KA) into
the striatum of rats resulted in neuropathological and neuro-
chemical features similar to those seen in HD. One of the most
prominent features which develop upon KA administration
was the selective loss of the striatal MSNs, which is also seen
100 in HD [15]. However, this KA-induced model of HD did not
spare interneurons of the striatum, which are known to be
preserved in HD neurodegeneration. In an attempt to estab-
lish a more accurate HD model Beal and colleagues used
intrastriatal quinolinic acid (QUIN) administration [16]. QUIN,
105 a known NMDA receptor agonist [17], is generated from Trp
via the KP. Injection of QUIN into rat striatum resulted in the
selective degeneration of striatal MSNs accompanied by the
survival of interneurons [16].
The finding that striatal degeneration is mainly due to the
110 loss of MSNs, a type of neuron which expresses NMDA
receptors [9], and that the decrease of NMDA receptors in
the striatum can be identified even in early, presymptomatic
stages of the disease [18,19] supported the notion that neu-
rons that express high level of NMDA receptors show
115increased vulnerability to degeneration [19]. It has been pro-
posed that the increased neuronal sensitivity might be
a consequence of mutant HTT-increased expression of the
NR1/NR2B subunit combinations of the NMDA receptors
found on the striatal MSNs [20]. The role of excitotoxicity in
120HD pathogenesis is further strengthened by reports of bene-
ficial effects of the GABAergic and antiexcitotoxic valproate on
the survival and locomotory activity in a transgenic mouse
model of the disease [21].
Besides excitotoxicity, disturbance in energy metabolism also
125contributes to the degenerative changes in HD. Early findings of
Stahl and colleagues revealed a significant decrease in the activ-
ity of the succinate dehydrogenase (SDH, an enzyme directly
linked to complex II of the electron transport chain (ETC)) in
postmortem HD brain samples [22]. In accordance with these
130findings, injection of the SDH inhibitor, malonate, into rat stria-
tum caused striatal lesions, which, however, could be prevented
by the systematic implementation of the NMDA receptor antago-
nist MK-801 [23]. These results suggest a link between energy
metabolism disturbance and excitotoxicity in HD.
135Further evidence for energy disturbances in HD was
reported by Jenkins and colleagues, who found elevated lactate
levels – an in vivo biomarker of impaired energy metabolism –
in the occipital cortex of HD patients. Moreover, the degree of
elevation of lactate levels was found to be correlated with
140disease duration [24]. A few years later, the same research
group found that oral administration of an essential cofactor
of the ETC, coenzyme Ql0 (CoQ10) resulted in a decrease in
cerebral lactate levels in HD patients [25]. These findings sup-
ported the hypothesis that associates energy disturbances with
145HD and gave hope of developing HD treatments by exploring
this aspect. Indeed, CoQ10 in combination with the NMDA
receptor antagonist remacemide has been proven to remedy
motor symptoms and abnormal weight-gain in the transgenic
mouse HD model [26]. This combination treatment also
150improved survival and decreased brain atrophy and striatal
aggregate number with a consistently lower rate of neuron
loss [27]. The positive results in animal models supported test-
ing CoQ10 and remacemide treatment in human HD patients,
and a multicenter, randomized, placebo-control study involving
155374 HD patients was conducted [28]. Although a trend toward
slower disease progression was observed, significant differences
between the group of patients treated with CoQ10 and the
placebo group was not achieved [28].
Dysfunctional mitochondria can also cause imbalances in
160ROS production and removal, leading to excessive protein,
lipid, and DNA oxidation which damages cells. In HD, mutant
HTT protein exacerbates ROS production [29]. Besides ROS,
reactive nitrogen species (RNSs) are also culprits in the oxida-
tive damage observed in HD [30]. The Ca++ increase caused by
165NMDA receptor activation induces neural nitric oxide synthase
(nNOS) leading to nitric oxide (NO•) formation, which can
contribute to the generation of RNSs [5]. Through the inhibi-
tion of ETC complexes II and III, NO• itself contributes to free
radical production that can lead to severe ATP depletion [30].
Article highlights
● A growing body of evidence supports the involvement of the KP in
HD pathogenesis.
● The upregulated state of the pathway results in the excessive pro-
duction of neurotoxic metabolites such as QUIN and 3-HK and
a decrease in the level of the neuroprotective KYNA.
● IDO1 catalyzes the first step of the KP and has various roles in
modulating immune responses.
● Inhibition of the first step of the KP was proven to be neuroprotec-
tive, as it shifted the pathway toward the formation of KYNA and
reduced QUIN-induced toxicity by decreasing the levels of 3-HK.
● Adjusting IDO1 activity could be beneficial in HD therapy as it would
restore the balance between neuroprotective and neurotoxic kynur-
enine compounds, modulate the upregulated inflammatory state and
alleviate depressive symptoms often present with the disease.
● Testing IDO1 inhibitor compounds that have been proven to be safe
in other areas of medicine could be a cost and time effective way of
trying novel therapeutic agents for HD.
This box summarizes key points contained in the article.
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170 Besides excitotoxicity, mitochondrial disturbances and oxi-
dative stress, inflammatory processes are also believed to be
related to neuronal damage in HD. Accumulation of activated
microglia has been reported in various regions of the HD brain
[31], and the overactivation and dysregulation of these cells
175 were found to correlate with the severity of the disease [32].
Reactive microglia in HD expressing complement proteins and
inflammation markers in high levels, likely contribute to neu-
rodegeneration [33]. Earlier findings in Alzheimer’s disease
(AD), that β-amyloid triggered complement activation, suggest
180 that a similar scenario might take place in HD, such as the
mutant HTT protein causing aggravated activation of the
complement system [33]. There are supporting data available
that inflammation might affect not only the central nervous
system (CNS) but also the periphery: elevated C reactive pro-
185 tein (CRP), neopterin, malondialdehyde and 4-hydroxynoenal
levels in blood samples of HD patients indicate a persistent
inflammatory state and high level of oxidative stress, possibly
reflecting neural damage and removal of the damaged cells in
the CNS [20]. Furthermore, increases were found in the levels
190 of IL23 and the soluble human leucocyte antigen-G in parallel
with increasing disease severity [34]. Therefore, the assess-
ment of the use of anti-inflammatory drugs in HD therapy is
clearly worth consideration.
Among the psychiatric symptoms of the disease, depres-
195 sion is detected strikingly frequently, affecting 40–50 percent
of the patients [35]. Presumably at least partly related to this,
suicide among HD patients is over five times more common
than in the general population [35], causing great concern
among patients, family, and caretakers.
200 2. The kynurenine pathway
2.1. A general overview of the kynurenine pathway
The KP is the main route of Trp metabolism outside of protein
synthesis, both in the periphery and in the CNS [36] (Figure 1). The
first and rate-limiting step in the pathway is the conversion of Trp
205 to N-formyl-L-kynurenine either by tryptophan 2,3-dioxygenase
(TDO) or by one of two IDO enzymes (IDO1 and IDO2). TDO is
mainly expressed in the liver regulating systemic Trp levels. IDO is
expressed in several cell types of the immune system (monocytes,
macrophages (MAs), dendritic cells (DCs) and microglia) and its
210 expression can be induced by various inflammatory signals, such
as interleukins (ILs), tumor necrosis factors (TNFs) and interferons
(IFNs), of which its main inducer is IFN γ [37].
Trp is transported into the CNS through the blood-brain-
barrier (BBB) by the large neutral amino acid transporter [38],
215 and once in the CNS, it can be converted into serotonin and
melatonin. However, in the CNS the vast majority of Trp –
more than 95% [39] – enters the KP.
The product of the first enzymatic conversion of the KP,
N-formyl-L-kynurenine is converted by formamidase into
220 L-kynurenine (L-KYN). L-KYN represents an important branch
point of the pathway as it can be metabolized alternatively
into kynurenic acid (KYNA), or anthranilic acid (AA), or 3-hydro-
xykynurenine (3-HK). KYNA is synthesized from L-KYN by kynur-
enine aminotransferases (KATs). There are four subtypes of KATs
225 (KATI-IV) [40] that can catalyze the conversion. The principal
enzyme from these in the human CNS is KATII [40,41]. Besides
KATs, L-KYN can also be metabolized by the kynureninase
enzyme (KYNU) and kynurenine 3-monooxygenase (KMO) form-
ing AA or 3-HK, respectively. 3-HK can be metabolized into
230xanthurenic acid (XA) by KATs, and both AA and 3-HK can be
converted into 3-hydroxyanthranilic acid (3-HAA), a metabolite
which is a free radical generator (like other compounds of the
pathway, see below) [20]. 3-HAA transforms into the unstable
2-amino-3-carboxymuconate-semialdehyde (ACMS) by 3–hydro-
235xyanthranilate oxidase (3-HAO). ACMS can give rise to either
picolinic acid (PIC) by conversion via aminocarboxymuconate-
semialdehyde decarboxylase (ACMSD) or to QUIN, a NAD+ and
NADP+ precursor metabolite, via a non-enzymatic conversion.
In summary, several steps of the KP produce metabolites
240that directly or indirectly affect neuron survival. KYNA is
a known antagonist of NMDA receptors [42] therefore it is
a promising therapeutic compound against glutamate-
induced excitotoxicity. In addition to NMDA receptors, KYNA
has also been reported to be antagonist of α7nicotinic acet-
245ylcholine receptors (nAChRs) [43]. The finding of human neo-
cortical and rat striatal glutamatergic axon terminals
expressing nAChRs, thus mediating glutamate release, offers
further possibilities of modulating glutamate excitotoxicity by
KYNA [44]. However, other data argue that the compound
250lacks nAChR-inhibiting ability [45,46]. The controversial result
might be due to the differences in research methods used.
Nonetheless, when considering potential therapeutic interven-
tions, elucidating the mechanism and effect of KNYA on
nAChRs is of great importance and highly relevant [43].
255Furthermore, the free-radical scavenger and antioxidant fea-
tures of KYNA further extend its therapeutic potential [47].
3-HK and 3-HAA are known free radical generators, thus con-
tribute to oxidative stress and neurodegeneration [48].
However, there are reports which show these molecules have
260antioxidant properties as well. Due to the amino and hydroxyl
aromatic group, they can be electron donors. Whether the pro-
or the antioxidant properties will dominate depends on the
activity of the redox system in the cell. In the presence of
copper, 3-HK and 3-HAA generate superoxide anion and
265hydrogen peroxide, which then lead to highly reactive and
cell-damaging quinonimine products [49]. QUIN is another
neuroactive metabolite of the KP, and it is a competitive
NMDA receptor agonist that, as mentioned above, is proposed
to be a key feature of HD excitotoxicity [50]. Accordingly,
270imbalance of the KP has been reported in several neurodegen-
erative diseases such as Parkinson’s disease (PD), AD and HD
(reviewed in [51]). Targeting specific enzymes of the pathway
seems to be a feasible way of amending the imbalance
between neuroprotectant and neurotoxic compounds, and
275by this prevent, or slowdown neurodegeneration.
2.2. Kynurenine pathway alterations in Huntington’s
disease
In light of the wide range of neuroactive kynurenines with their
various effects on neuron viability and function, it is not surpris-
280ing that the involvement of the pathway in HD has gathered
a lot of interest in the past decades. In the following section, we
will discuss some of the findings on the relationship between
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the KP and HD. Tables 1 and 2 summarize changes in enzyme
activity and kynurenine metabolite levels detected in HD
285 patients and/or in animal models of the disease.
The KP is proposed to contribute to the development and
progression of HD by several mechanisms. Here we consider
those which are linked directly to KP functions. On one hand,
the imbalance in the production of NMDA receptor agonist
290 (QUIN) and antagonist (KYNA) compounds can lead to exciti-
toxicity via NMDA receptor overactivation. On the other hand,
excessive amounts of 3-HK and 3-HAA can lead to ROS
accumulation thus causing oxidative stress that leads to neu-
rodegeneration [20]. Furthermore, the activity of KP might
295greatly affect neurotransmitter production thus neuropsychia-
tric symptoms of the disease.
Mutant HTT can be one of the culprits of KP upregulation and
the consequent rise in 3-HK and QUIN levels leading to ROS
toxicity. It has been proposed that cytokines secreted by mutant
300HTT-expressing dysfunctional neurons induce microglial activa-
tion [52]. The upregulated state of KP in activated microglia
results in elevated levels of 3-HK and QUIN, leading to neuronal
Figure 1. The kynurenine pathway with its neuroactive metabolites highlighted.
Among the KP metabolites KYNA, 3-HK and 3-HAA are known to have neuroactive properties. KYNA, due to its NMDA receptor antagonism, antioxidant and free radical scavenging features,
is a neuroprotective compound. On the contrary, 3-HK and 3-HAA can cause excessive ROS production, while QUIN is a known NMDA receptor agonist, therefore a disproportionate level of
these metabolites can lead to neurodegeneration.
Abbreviations: ROS: reactive oxygen species; Trp: tryptophan; IDO1,2: indoleamine 2,3-dioxygenase; TDO: tryptophan-2,3-dioxygenase; KYN: kynurenine; KAT: kynurenine aminotransferase;
KYNA: kynurenic acid; KYNU: Kynureninase; AA: Anthranilic acid; KMO: Kynurenine-3-monooxygenase; 3-HK: 3-hydroxy-L-kynurenine; XA: Xanthurenic acid; 3-HAA: 3-hydroxyanthranilic acid;
3-HAO: 3-hydroxyanthranilate-3,4-dioxygenase; ACMS: 2-amino-3-carboxymuconate-semialdehide; ACMSD: Aminocarboxymuconate-semialdehyde-decarboxylase; PIC: Picolinic acid; QUIN:
quinolinic acid; QPRTase: quinolate phospho-ribosyltransferase; NAD+: Nicotinamide adenine dinucleotide, NMDA: N-methyl-D-aspartate
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damage [52]. In another scenario, mutant HTT protein expressed
directly in astrocytes and microglia leads to KP upregulation and
305 resultant ROS overproduction [53].
The upregulated state of the pathway in the disorder was
revealed by a study of Stoy and colleagues, who determined
different KP metabolite levels in blood samples of HD patients
[20]. The levels of KYN in HD patient samples were found to be
310 double that of controls, suggesting an enhanced Trp to KYN
conversion due to the increased activity of either IDO and/or
TDO. This assumption is in accordance with the elevated KYN/Trp
ratio (an indicator of IDO activity) found in HD patients [20], as no
difference was observed between patients and controls either in
315 Trp or KYNA levels. The decreased KYNA/KYN ratio resulting from
elevated KYN and unchanged KYNA levels suggests a lower KAT
activity in HD. Besides KYN, a significant increase was observed in
the amount of XA in HD patients, whereas their levels with
respect to the free radical generators 3-HAA and 3-HK were
320significantly decreased. Blood levels of QUIN showed large varia-
tions, both in�patient and control study groups, not revealing
significant differences between them [20].
An upregulated state of the pathway was also found in
animal models of the disease. A significant decrease was
325found in the levels of Trp, accompanied with an increase in
the KYN/Trp ratio in the brain of the 3-nitropropionic acid
(3-NP) toxin mouse model [13]. Besides Trp, a decrease in
cerebellar 3-HK levels was also observed [13].
Though analysis of blood samples did not reveal any
330change, a decrease in the level of the neuroprotective KYNA
has been reported in HD postmortem cerebral cortex [14],
putamen [54], nucleus caudatus [55], and CSF [54,56].
A decrease in levels of KYNA occurs simultaneously with an
increase in the KYN/KYNA ratio, suggesting reduced KAT
335enzyme activity in HD brain [54], as was found in peripheral
blood. Results of Jauch and colleagues strengthened this
hypothesis, by finding significant decreases of KATI and II
activities in the striatum samples of HD patients [55].
Interestingly, change in the enzyme activity was not found in
340other brain areas, suggesting the impairment of KYNA synth-
esis to be selective to the striatum [55].
Besides KATs, changes in the activity of another enzyme,
3-HAO has been reported in HD cases [57]. In contrast with
KATs, 3-HAO activity was found to be increased in postmortem
345HD brain, most prominently in the striatum [57]. As astrocytes
contain 3-HAO, it was proposed that the increase of enzyme
activity might be partly due to astrogliosis, characteristic of HD
striatum [57]. The involvement of astrocytes in HD pathogen-
esis and disease progression is multifaceted. Astrocytes lack
Table 1. Reported activity changes of kynurenine pathway enzymes that affect
Huntington’s disease.
Enzyme
Change in
activity Species Sample Reference
IDO ↑ Human blood [20]
KYNU ↓ Mouse (R6/2) brain [64]
KAT ↓ ? Human striatum [54]
↓ Human striatum [55]
↓ ? Human blood [20]
KMO ↑ Mouse (R6/2) brain [64]
3-HAO ↑ Human brain (most
prominently in
striatum)
[57]
Abbreviations: IDO: indoleamine 2,3-dioxygenase; KYNU: kynureninase; KAT: kynur-
enine aminotransferase; KMO: kynurenine monooxygenase; 3-HAO: 3-hydroxyan-
thranilate-3,4-dioxygenase; = : no detectable change; ↑: increase; ↓: decrease
Table 2. Kynurenine metabolite level changes in Huntington’s disease.
Compound Change in levels Species Sample Reference
Trp = Human blood [20]
↓ Mouse (3-NP toxin model) str, hippocampus, brainstem, crb [13]
KYN ↑ Human blood [20]
KYNA ↓ Human ctx [14]
↓ Human putamen [54]
↓ Human nucleus caudatus [55]
↓ Human CSF [54,56]
↑ (trend) Human ctx and str [63]
↑ (trend) Mouse (full lenght htt) ctx and str [63]
= Human blood [20]
3-HK ↑ Human ctx and str [62]
↑ Human Temporal and frontal ctx [59]
↑ Human ctx and str [63]
↑ Mouse (full lenght htt) ctx and str [63]
↑ Mouse (R6/2) ctx, crb and str [61]
↑ Mouse (HdhQ92 and HdhQ111; 15 and 17 month-old) ctx, crb and str [61]
↑ Mouse (YAC128; 8 and 12 month-old) ctx, crb and str [61]
↑ Human (early HD) neoctx and neostr [60]
= /↓ (trend) Human (advanced HD)
↓ Human blood [20]
↓ Mouse (3-NP toxin model) crb [13]
3-HAA ↓ Human blood [20]
XA ↑ Human blood [20]
QUIN ↑ Mouse (HdhQ92 and HdhQ111; 15 and 17 month-old) ctx and str [61]
↑ Mouse (YAC128; 8 and 12 month-old) ctx and str [61]
= Human Putamen and frontal ctx [59]
↑ Human (early HD) neoctx and neostr [60]
= /↓ (trend) Human (advanced HD)
= (large variation) Human blood [20]
Abbreviations: Trp: tryptophan; 3-NP: 3-nitropropionic acid; KYN: kynurenine; KYNA: kynurenic acid; 3-HK: 3-hydroxy-L-kynurenine; 3-HAA: 3-hydroxyanthranilic acid; XA:
xanthurenic acid; QUIN: quinolinic acid; = : no detectable change; ↑: Increase; ↓: Decrease; ctx: Cortex; CSF: Cerebrospinal fluid; str: Striatum; crb: Cerebellum; HD:
Huntington’s disease
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350 KMO, therefore, while capable of KYNA and KYN formation,
they only produce the down-stream neurotoxic metabolites
such as QUIN and 3-HK in small amounts or not at all [58].
Moreover, astrocytes possess IFNγ-inducible quinolate phos-
pho-ribosyltransferase (QPRTase) which degrades even the
355 small amounts of QUIN produced from AA in astrocytes [58].
QPRTase, however, is easily saturated which can lead to QUIN
accumulation. Increase in QUIN levels can also be the result of
excessive KYN production, as it can be converted into the
neurotoxic metabolite by the infiltrating macrophages and
360 activated microglia [58]. Thus, under normal circumstances
astroglia have neuroprotective effects due to their QUIN cata-
bolizing and KYNA synthesizing ability, however, in the pre-
sence of activated microglia and macrophages astrocytes
cause neuronal damage indirectly [58]. These findings raise
365 the possibility of interfering QUIN-related excitotoxicity and
consequent neurodegeneration by diminishing the formation
of KYN in astrocytes via inhibition of the first enzyme of the
pathway, IDO1.
The observation that HD symptoms can be modeled by
370 injection of QUIN into murine striatum predicted the com-
pound would contribute to the disease in humans as well.
Early findings by Reynolds and colleagues did not support this
hypothesis [59], more recent results on the other hand are in
accord with the idea, which assumes a role for QUIN in HD
375 neurodegeneration: elevated levels of the NMDA receptor
agonist have been found in both HD patients [60] and several
animal models of the disease [61]. Further findings strongly
suggest that QUIN, alongside 3-HK, has a role primarily in the
early stages of the disease. Postmortem investigation of HD
380 neocortex and neostriatum revealed that QUIN and 3-HK
levels were elevated in early stages of the disease, however,
with disease progression the levels of these metabolites
seemed to normalize or even decrease [60].
Elevation in the level of 3-HK has been described repeat-
385 edly, both in postmortem human HD brain tissue and animal
models [59–63]. Recent findings by Sathyasaikumar and col-
leagues indicate that an increase in 3-HK levels can result from
either increased KMO or decreased KYNU activity, as these two
enzymes are responsible for the synthesis and degradation of
390 3-HK, respectively [64]. However, it should be emphasized that
approximately 60% of CNS resident L-KYN – that is the pre-
cursor of 3-HK – is transported through the BBB from the
periphery [65]. Therefore, it cannot be overlooked that besides
the combined effects of increased synthesis and reduced
395 degradation levels, the accelerated influx of L-KYN is likely
a result of increased L-KYN production in the periphery,
which then also contributes to the elevated 3-HK levels in
the CNS.
In a study, Guidetti et al. found that elevated 3-HK levels
400 were accompanied by a parallel elevation of KYNA in the
neostriatum of stage 1 HD patients and in brain of
a transgenic mouse HD model [63]. The increase of 3-HK levels
was, however, more prominent, resulting in a high 3-HK/KYNA
ratio [63]. As microglia possess the whole enzyme apparatus of
405 the KP, while, as mentioned above, astrocytes lack KMO, the
marked elevation of 3-HK is presumably due to overactivated
microglia. So this observation can serve as a further indication
of the dysregulation in these cells in HD pathology [63].
Considering the above, one might propose that a more fea-
410sible way of intervening in the KP in HD is to decrease QUIN-
related excitotoxicity by directly inhibiting the 3-HAA enzyme.
However, blocking the pathway before the formation of QUIN
could lead to the accumulation of other upstream metabolites,
such as the free radical-generating, therefore potentially toxic,
4153-HK and 3-HAA. This does not exclude 3-HAA as a target of
therapeutic intervention though but highlights the complexity
of interfering in the pathway.
KP metabolites might be used as new biomarkers for HD by
monitoring the changes in their levels. An ongoing trial
420(HDClarity, ClinicalTrials.gov identifier: NCT02855476) aims to
discover such novel biomarkers in the CSF, and uncover rela-
tionships between disease severity and KP metabolite levels.
The study is expected to be completed by 2020, and hopefully
will provide important new information on potential therapeu-
425tic targets as well.
2.3. Attempts to modulate elements of the kynurenine
pathway as therapeutic targets for Huntington’s disease
Observations that imbalances of toxic and neuroprotective
metabolites of the KP play roles in HD draw attention to
430elements of the pathway as potential therapeutic targets
offering means to restore the balance (reviewed in [66]). This
can be envisioned either by enzyme modulation, thus enhan-
cing the production of the neuroprotectant KYNA or by utiliz-
ing its analog or alternatively its prodrug. The combined use
435of L-KYN and probenecid has been shown to have protective
effects when considering both behavioral and neurochemical
aspects in a QUIN-induced rat model of HD [67]. Similarly,
beneficial effects have also been reported for the synthetic
prodrug, 4-chlorokynurenyne (4-CL-KYN) in a QUIN and mal-
440onate-induced rat HD model [68]. 4-CL-KYN is the prodrug of
7-chlorokynurenynic acid (7-CL-KYNA), a selective glycin/
NMDA receptor antagonist. 4-CL-KYN, administered in intras-
triatal infusion, was locally metabolized into 7-CL-KYNA and
attenuated the toxic effects of both QUIN and malonate [68].
445Lately, intraperitoneal injection of a novel KYNA analog,
N-(2-N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxa-
mide hydrochloride was found to extend survival, improve
motor functions, increase body weight, and prevent the loss
of striatal neurons in a transgenic mouse model of the dis-
450ease [69].
Among therapy approaches based on altering enzyme
activities, targeting KMO has so far been in the spotlight
[70]. The aim of such approaches is to enhance KYNA produc-
tion by blocking the conversion of L-KYN to 3-HK. Elevation in
455brain KYNA levels can be achieved by intraventricular applica-
tion of nicotinylalanine [71] and a novel peripheral KMO inhi-
bitor, JM6, which is the prodrug of Ro 61–8048 [72]. Though
neither JM6 nor Ro 61–8048 can cross the BBB, an elevation in
the level of KYNA can be observed in the CNS even after oral
460administration of JM6. This is likely due to peripheral accumu-
lation of the BBB penetrant KYN, which is metabolized into
KYNA after entering the brain [72].
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Based on the quinolate excitotoxicity-hypothesis, targeting
NMDA receptors might also seem to be a reasonable thera-
465 peutic approach for HD. However, the feasibility of such efforts
should be weighed with great precaution: in transgenic HD
mice low-dose memantine treatment, which causes inhibition
of extrasynaptic NMDA receptors, resulted in an improvement
in the symptoms, while blockage of synaptic receptors by
470 high-dose memantine had the opposite effects [73]. Synaptic
NMDA receptor activity was protective against mutant Htt
protein, while activation of extrasynaptic NMDA receptors
decreased neuronal survival [73].
Similarly to NMDA receptor-modulating therapies, regulat-
475 ing KYNA levels also requires care as there is a growing body
of evidence on the negative effects of elevated KYNA levels on
cognitive functions under certain circumstances [74].
3. Indoleamine 2,3-dioxygenase
3.1. Indoleamine 2,3-dioxygenase enzymes
480 IDO is the first and rate-limiting enzyme of the KP catalyzing the
conversion of Trp to N-formyl-L-kynurenine (Figure 1). In
humans, two IDO enzymes have been identified, which are
referred to as IDO1 and IDO2. In papers published before the
discovery of IDO2 in 2007 [75,76], the ‘IDO’ designation was used
485 in general and some studies even nowadays use the term ’IDO’
for IDO1. For clarity, we will use the IDO1 and IDO2 nomencla-
ture, distinguishing the two enzymes whenever possible.
The genes encoding IDO1 and IDO2 are adjacent on chro-
mosome 8, suggesting their common origin [77]. The two
490 enzymes have 43% amino acid identity, including residues
critical for catalytic activity [75]. Both IDO can convert the
same substrates (L- and D-Trp, tryptamine, 5-hydroxy-
typtamine, serotonin), IDO1 however, has higher catalytic
activity [78]. In fact, the Michaelis Constant (Km) of IDO2 for
495 Trp is over 100-fold higher than physiological Trp concentra-
tions which makes the direct role of IDO2 in Trp degradation
questionable and suggests another, so far unidentified natural
substrate for the enzyme [79]. Available data suggest low
levels of IDO2 expression in liver, testis, and thyroid [80]. In
500 addition, frequent occurrence of mutant IDO2 alleles leads to
non-functioning IDO2 in 50% of the population [76].
More information is available regarding IDO1 activity, tis-
sue-specific expression, and functions in the human body.
Under physiological conditions, IDO1 expression can be
505 detected in several human tissues, such as lymphoid organs,
epithelial cells of the female genital tract, placenta, and lung
parenchyma (for a review see [80]). IDO1 is also expressed in
various immune cells, such as DCs, monocytes, MAs, and
microglia [81]. Its expression can be stimulated by various
510 immunomodulators, including IFNs, lipopolysaccharides (LPS),
ILs (IL1β, IL6), TNFs (TNFα) and prostaglandins (PGE2), of which
the strongest inducer seems to be IFNγ [37,80]. IDO1 has an
important role in regulating the immune system and main-
taining immune-homeostasis. It can exert its immune-
515 modulating effects both by decreasing the amount of avail-
able Trp and by producing kynurenines (see below).
In short, despite structural similarities with IDO1, the low
catalytic activity, low expression level and high frequency of
non-functional variant forms make IDO2 less favorable, and
520IDO1 a more promising target for therapeutic approaches.
3.2. The effects of indoleamine 2,3-dioxygenase 1 on
immune functions
It is beyond the scope of this review to provide
a comprehensive discussion of the diverse functions of IDO1
525and the affected mechanisms. Instead, in this section, we
highlight the complexity of IDO1’s contribution to immune
regulation (Figure 2).
The first report on the role of IDO in immune responses was
published by Munn and colleagues [82] who proposed that
530allogeneic fetal rejection in a mouse model was prevented by
the T-cell modulating effect of placental cells expressing Ido.
They hypothesized that by diminishing the level of available
Trp, Ido inhibited maternal T-cell responses, which led to the
loss of the allogeneic fetus [82]. The mechanism by which
535T cell suppression is achieved has been argued recently and
proposed to be due to the formation of kynurenine metabo-
lites, rather than to Trp depletion [83]. Either way, it seems
that IDO1 via Trp degradation or metabolite synthesis can
exert immune modulating effects (for a review see [84]).
540IDO1 also exhibits inhibitory effects on T effector cells (Teff),
thus it has anti-inflammatory properties. One way Teff cells can be
inhibited is indirectly, by promoting naive T-cell differentiation
into regulatory T-cells (Treg) [85]. Kynurenine metabolites were
also found to be able to stabilize the immunosuppressive pheno-
545type of Treg cells, avoiding their transformation into pro-
inflammatory T helper-like effector cells at inflammation sites [86].
Direct inhibition of Teff cells by IDO1 can be achieved by
inducing clonal anergy [87], cell cycle arrest, and apoptosis [88].
Besides affecting Teff cell survival, the activation of IDO1 and
550consequent production of kynurenines results in cell cycle arrest
and apoptosis of B and natural killer (NK) cells, as well [88].
Under certain circumstances, however, instead of repres-
sing, IDO1 can stimulate B cell responses and cause the activa-
tion of autoreactive B cells leading to autoimmune processes
555[89]. The Janus-faced regulatory role of IDO1 in immune mod-
ulation is well illustrated by its effects on MAs. On the one
hand, activated MAs expressing IDO1 deplete the Trp supply
in their microenvironment, in this way enhancing their sensi-
tivity to LPSs. This leads to an increase in their IL-6 production,
560promoting inflammatory processes [90]. On the other hand,
over-expression of IDO1 triggers MAs to differentiate into
immunosuppressing M2, rather than “effector” M1, thus pro-
moting an immune tolerant state [91]. This self-regulatory
mechanism enables the avoidance of excessive immune
565response. In certain infectious states, the prevention of exag-
gerated immune response is reached via increased IDO1
expression of DCs. The augmented expression of the enzyme
leads to the excessive formation of KYN, which induces apop-
tosis of neutrophil granulocytes (NGs) at the site of inflamma-
570tion [92]. Due to the consequent decrease in IFNγ production,
the accumulation of further NGs is limited, thus restraining the
local immune response [92].
By controlling the quantity of available Trp through the
formation of kynurenine metabolites, IDO1 has indirect effects
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575 on serotonin synthesis (Figure 1). In light of data on the
involvement of the serotonin system in depression, targeting
IDO1 also offers the possibility to manage mood alterations
often present in HD.
In light of its diverse immune-modulating effects and its
580 link with other metabolic pathways, not surprisingly, IDO1
has been implicated in several diseases in which changes in
immunoregulation are observed. Besides fetal rejection [82]
expression and/or function of IDO1 has been investigated
and found to be altered in infectious [93,94] and autoim-
585 mune diseases [95,96], in the immune-escaping process of
tumors [97] and in neurodegenerative diseases [98,99], such
as HD.
3.3. Indoleamine 2,3-dioxygenase as a potential
therapeutic target for Huntington’s disease treatment
590 Despite being the rate-limiting enzyme in a pathway that con-
verts Trp to neuroactive compounds, and having widespread
function in immune modulation, data on IDO1 in respect of its
role in HD are scarce. Nonetheless, information from both animal
models and analysis of human tissues strongly suggests the
595 involvement of the enzyme in the disease, making it worthy of
attention in the search for new therapeutic targets for HD.
The observation that Ido1 expression is higher in wild-type
mouse striatum compared to other brain regions, might serve
as an indication of the role of IDO1 in HD [9]. Ido1 activity can
600 be detected most prominently in MSNs and striatal astrocytes,
suggesting that primarily these cells contribute to striatal Ido1
expression [9]. Considering that MSNs are primarily prone to
neurodegeneration in HD and that astrogliosis is a hallmark of
the disease, these findings raise intriguing questions regarding
605the role of IDO1 in HD.
Despite the loss of cells that proposed�ly contribute most to
IDO1 expression in the striatum, elevated Ido1 activity could be
detected in the striatum of YAC128 mice, a model of the disease,
resulting in increased levels of neurotoxic 3-HK production [9].
610Increased enzyme activity was also reported in the blood of HD
patients [20]. The decrease in the level of KYN after Trp depletion
was found to be less prominent in HD patients compared to
healthy controls, suggesting that the activity of IDO1 is higher in
HD even during at shortage of its metabolite [20].
615These findings point to the possibility of IDO1 inhibition as
a therapeutic approach in HD. Results of studies conducted
using fruit fly and murine models support the rationale of such
an approach. In a Drosophila melanogaster HD model, genetic
inhibition of the Tdo2 enzyme was found to be protective
620against mutant Htt protein neurotoxicity [100]. Drosophila
possesses neither Ido1 nor Ido2 therefore Tdo2 is the first,
rate-limiting enzyme of the pathway, which converts Trp to
KYN [100]. The inhibition of Tdo2 shifts the pathway toward
the formation of KYNA, thus enhancing neuroprotection [100].
625One might propose that inhibition of IDO1 – as a functional
analog of TDO2 – could have a similar effect both in higher
model organisms and in humans, therefore, it might serve as
an alternate way to improve neuroprotection.
Supporting this concept, it was found that in the absence
630of Ido1 expression in the striatum of Ido1 knockout (Ido-/-)
Figure 2. The immunomodulatory roles of indoleamine 2,3-dioxygenase.
IDO1 affects the activity of various immune cells, such as T and B cells, NK cells, macrophages, and neutrophile granulocytes via Trp depletion and the production of KP metabolites.
Depending on the microenvironment and presence of further inflammatory molecules and immune cells, IDO1 can lead to both the progression of inflammatory processes and immune
suppression.
Abbreviations: IFNs: Interferons; ILs: Interleukins; TNFs: Tumor necrosis factors; LPS: Lipopolysaccharide; PGs: Prostaglandines; Trp: Tryptophan; IDO1: Indoleamine 2,3-dioxygenase 1; Treg:
Regulatory T-cell; Teff: Effector T-cell; NK cells: Natural killer cells; MAs: Macrophages; NGs: Neutrophil granulocytes.
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mice, neurons in the striatum became less sensitive to NMDA
receptor-mediated excitotoxicity, as it was demonstrated by
the reduction of QUIN-induced neurotoxicity [101]. This can be
partly explained by the significantly decreased levels of 3-HK
635 observed in striatum of Ido-/- mice, as 3-HK has been shown to
potentiate QUIN toxicity [102]. Interestingly, the lack of the
enzyme did not cause any change in the levels of QUIN and
KYNA [101].
Findings of Forrest and colleagues further strengthen the
640 involvement of IDO1 activity in the progression of HD.
Prominently lower levels of Trp and higher Trp/KYN ratios
(indicating higher activity of IDO1 enzyme) were observed in
most severely affected HD patients compared to patients with
less severe clinical symptoms. The results of negative correla-
645 tion between the number of CAG repeats and Trp levels, while
positive correlation between CAG repeat number and KYN/Trp
ratio suggests a link between disease severity and IDO1 acti-
vation [34,103].
4. Conclusion
650 Overall, research focusing on IDO1 has uncovered several
effects of the enzyme on pathways altered in HD. These data
support the consideration of IDO1 as a therapeutic target for
the disease and strongly warrant further studies exploring
additional details of the processes affected. Findings accumu-
655 lated so far strongly suggest that inhibition of the first step of
the KP, such as decreased IDO1 activity, can be beneficial in
preventing neuron loss. A supporting argument for targeting
IDO1 can also be that by altering the balance of kynurenine
metabolites via modulation of the activity of this enzyme,
660 both the direct effects of neuroprotective compounds of the
KP can be exploited, and indirectly, changes can be triggered
in ROS production and in immune responses that are sug-
gested to play roles in HD, as indicated by the consistent
elevation of inflammatory markers in HD blood samples [20].
665 Last, but not least, through inhibition of IDO1, the metabo-
lism of Trp can be shifted toward the synthesis of serotonin;
thus, inhibition of IDO1 might also serve as a therapeutic
invention against depressive symptoms in HD. Nonetheless,
to our knowledge, no therapeutic interventions targeting the
670 IDO enzyme with the intention for HD therapy have yet been
tested.
5. Expert opinion
Identification of possible therapeutic targets in HD is urgent,
as despite the severe motor, psychiatric and cognitive symp-
675 toms, the available treatment is mainly symptomatic. Recently
HTT gene expression modulation by antisense oligonucleotide
(ASO) has been presented as a promising therapeutic
approach for HD treatment (IONIS-HTTRx; ClinicalTrials.gov
identifier:�NCT02519036; reviewed in [104]). A phase 1/2a
680 clinical trial has been completed with successful outcomes
regarding both tolerability and effectiveness, demonstrating
the possibility of the ASO approach in HD treatment [105].
Gene expression modulating therapies, however, have several
limitations (mode of implementation, age of the patients,
685existing comorbidities, etc.), thus discovering other therapeu-
tic methods is still clearly warranted.
Imbalances of the KP have been reported in HD on several
occasions. Overproduction of QUIN leads to NMDA receptor-
mediated excitotoxicity, a well-documented mechanism in HD
690pathogenesis. Elevated 3-HK production contributes to aug-
mented oxidative stress and consequent mitochondrial
damage, and potentiates QUIN-induced toxicity of neurons.
Consequently, modulating the activity of KP enzymes involved
in the production and degradation of these metabolites might
695offer a possibility for therapeutic intervention. IDO1 catalyzes
the first reaction of the KP and is the rate-limiting enzyme of
the metabolic route. By modulating IDO1 activity, the balance
of kynurenine metabolites could be shifted toward the pro-
duction of neuroprotectant, rather than neurotoxic
700compounds.
Reflecting the neurodegeneration and consequent removal
of degenerating cells, elevated inflammatory markers in HD
patients strongly suggests a persistent state of inflammation.
In light of the fact that IDO1 also plays a pivotal role in
705regulating immune mechanisms, the enzyme could be
a potential target for the modulation of inflammatory pro-
cesses related to HD as well.
IDO1 inhibition might also be beneficial in ameliorating
depressive symptoms associated with the disease, as various
710abnormalities of the serotoninergic system have been linked
to depression, among these, change in the Trp level directly
affected by IDO1 [106]. By inhibition of IDO1, Trp utilization via
the KP is inhibited, thus higher level of amino acid is available
as precursors for serotonin synthesis. The notion regarding the
715role of IDO1 in the development of depression is supported by
the finding that peripheral inflammation, which is an inducer
of IDO1, was shown to contribute to the development of
depressive symptoms [107].
Despite the increasing body of evidence thus far accumu-
720lated that suggests dysregulation of KP in HD and data
demonstrating the beneficial effects of IDO1 inhibition, no
therapeutic intervention targeting the enzyme has been pro-
posed for HD treatment. This might be due to the very com-
plex nature of HD pathogenesis: even though several
725pathological changes have been proven or suggested to con-
tribute to the disease, exploration of the exact mechanisms of
pathogenesis requires further elucidation. The functional con-
sequences of IDO1 activity are also diverse and finely tuned
(e.g. self-defense against overactivated immune response ver-
730sus exaggerated immunotolerance leading to autoimmunity);
therefore, the elucidation of its precise effects under specific
conditions poses formidable challenges. To explore the var-
ious possibilities and identify causal connections, which might
further underline reasons to consider IDO1 as a therapeutic
735target for HD, extension of our knowledge on the variation in
enzyme activity in the disease state and the contribution of
that to HD is highly warranted.
However, inhibition of the enzyme can have side effects
due to its complex role in immune regulation. At the site of
740inflammation, Th1 cells producing IFNγ and other cytokines
induce the expression of IDO1, causing the decrease of locally
available Trp and increasing the formation of KP metabolites.
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These changes lead to the decrease of effector T-cell
responses, thus preventing exaggerated immune responses,
745 suggesting that IDO is a component of a self-regulatory,
negative feedback loop. It can easily be conceived that dis-
turbance to this finely tuned self-regulatory mechanism –
either by pharmacological enzyme inhibition or by genetically
determined decreased enzyme activity – can lead to
750 unwanted and excessive immune response. Such an effect
was demonstrated in a mouse model of colitis, in which
inhibition of the enzyme resulted in a higher mortality [108].
An exaggerated immune response might also lead to flair ups
of autoimmune diseases, as was demonstrated in a proteolipid
755 protein (PLP)-induced experimental autoimmune encephalo-
myelitis (EAE) mouse model of multiple sclerosis [96]. During
inflammation in the CNS, higher IDO activity was measured,
showing correlation to the clinical onset and severity of the
disease [96]. It was found that treatment with the IDO inhibitor
760 1-Mt of EAE animals caused the exacerbation of the disease as
demonstrated by the significantly higher clinical scores of the
1-Mt-treated group compared to untreated animals [96].
Precautions are warranted in enzyme inhibition, not only in
the case of inflammatory processes but in pregnancy and
765 tissue transplantant as well. Diminished immune tolerance in
the placenta can result in the loss of allogeneic concepti as
demonstrated by Munn and colleagues using the 1-Mt treated
mouse model [82]. Furthermore, Ido-/- mice receiving bone
marrow transplants showed a more severe course of graft-
770 versus-host colitis compared to the wild-type recipients [109].
Besides side effects, the selectivity of IDO1 inhibitors is
another cardinal question that should not be overlooked.
Some of the monoamine oxidase (MAO) inhibitors were
found to inhibit IDO1. One cannot exclude the possibility of
775 inhibitors of IDO1 affecting other enzymes as well [110].
Considering the above mentioned, one might propose that
a more feasible way of intervening the KP in HD is to decrease
QUIN-related excitotoxicity by directly inhibiting the 3-HAA
enzyme. However, blocking the pathway before the formation
780 of QUIN could lead to the accumulation of other upstream
metabolites, such as the free radical-generating, therefore
potentially toxic, 3-HK and 3-HAA. This does not exclude
3-HAA as a target of therapeutic intervention but highlights
the complexity of interfering in the pathway.
785 A possible way to avoid the above-mentioned side effects
of IDO inhibition is careful selection of the patients who
receive such enzyme therapy. Application of IDO inhibitors in
individuals suffering from autoimmune disease or are subjects
of organ or tissue transplant should be carried out with great
790 precaution and need monitoring of inflammatory processes.
Although inhibitors of IDO1 developed for and tested
specifically in HD are nonexistent, IDO1-inhibiting com-
pounds are under trial as promising drugs for cancer ther-
apy, as decreasing the enzyme’s activity can help to avoid
795 immune surveillance of malignant tumors [111]. Out of the
compounds tested in this respect, two have already
reached clinical trial phase [111]. These are 1-methyl-
D-tryptophan (1-D-MT), which was the first compound
found to be potent in the micromolar range, and
800 INCB24360, a hydroxyamidine derivate. Though the number
of specific IDO1 inhibitors so far developed is scarce,
hopefully, drug research will be able to develop other
compounds for cancer and other diseases. Results of cancer
research involving IDO1 activity modulation carry hope for
805therapeutic developments for HD as well. Compounds that
have been proven to be safe based on trials in one area of
medicine, hold great advantages for trials in other areas,
improving time and cost efficiency, regardless of whether
they have been effective with respect to the primary pur-
810pose of their development.
All things considered, IDO1 might serve as a valuable novel
therapeutic target for HD as it offers possibilities for benefi-
cially modulating neurodegeneration, inflammation, and ser-
otoninerg neurotransmission simultaneously. As these
815complex processes are all affected in HD, IDO1 is clearly an
unexplored target in the search for new approaches to HD
therapy. Ongoing trials aimed at recognizing KP metabolites
as biomarkers for HD and the thus far developed IDO1 inhibi-
tors under clinical trial justify further therapeutic
820developments.
Funding
This paper was not funded. The current work was supported by Economic
Development and Innovation Operational Programme - GINOP-2.3.2-15-
2016-00034, Hungarian Brain Research Program − Grant No. 2017-
8251.2.1-NKP-2017-00002 NAP VI/4, Ministry of Human Capacities, Hungary
grant 20391-3/2018/FEKUSTRAT and the MTA-SZTE Neuroscience Research
Group of the Hungarian Academy of Sciences and the University of
Szeged. AQ2�
Declaration of interest
830The authors have no relevant affiliations or financial involvement with any
organization or entity with a financial interest in or financial conflict with
the subject matter or materials discussed in the manuscript. This includes
employment, consultancies, honoraria, stock ownership or options, expert
testimony, grants or patents received or pending, or royalties.
835Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial or other
relationships to disclose
References
Papers of special note have been highlighted as either of interest (•) or of
840considerable interest (••) to readers.
1. Novak MJU, Tabrizi SJ. Clinical review Huntington’s disease. BMJ.
2010;340:34–40. AQ3�
2. Baig SS, Strong M, Quarrell OWJ. The global prevalence of
Huntington’s disease: a systematic review and discussion.
845Neurodegener Dis Manag. 2016;6:331–343.
3. Macdonald ME, Ambrose CM, Duyao MP, et al. A novel gene
containing a trinucleotide that is expanded and unstable on
Huntington’s disease chromosomes. Cell. 1993;72:971–983.
4. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and
850potential therapeutical targets in Huntington’s disease. Physiol
Rev. 2010;10:905–981.
5. Sorolla MA, Rodríguez-Colman MJ, Vall-Llaura N, et al. Protein
oxidation in Huntington disease. BioFactors. 2012;38:173–185.
6. Perutz MF. Glutamine repeats and neurodegenerative diseases:
855molecular aspects. Trends Biochem Sci. 1999;24:58–63.
10 F. A. BOROS ET AL.
7. Kuemmerle S, Gutekunst C, Klein AM, et al. Huntingtin aggregates
may not predict neuronal death in Huntington’s Ddsease. Ann
Neurol. 1999;46:842–849.
8. Arrasate M, Mitra S, Schweitzer ES, et al. Inclusion body formation
860 reduces levels of mutant huntingtin and the risk of neuronal death.
Nature. 2004;431:805–810.
9. Mazarei G, Budac DP, Lu G, et al. Age-dependent alterations of the
kynurenine pathway in the YAC128 mouse model of Huntington
disease. J Neurochem. 2013;127:852–867.
865 10. Ehrlich ME. Huntington’s disease and the striatal medium spiny
neuron: cell-autonomous and non-cell-autonomous mechanisms
of disease. Neurotherapeutics. 2012;9:270–284.
11. Yager LM, Garcia AF, Wunsch AM, et al. The ins and outs of the
striatum: role in drug addiction. Neuroscience. 2015;301:529–541.
870 12. Benarroch EE. Effects of acetylcholine in the striatum: recent
insights and therapeutic implications. Neurology. 2012;79:247–281.
13. Veres G, Molnár M, Zádori D, et al. Central nervous system-specific
alterations in the tryptophan metabolism in the 3-nitropropionic
acid model of Huntington’s disease. Pharmacol Biochem Behav.
875 2015;132:115–124.
14. Beal MF, Matson WR, Storey E, et al. Kynurenic acid concentrations
are reduced in Huntington’s disease cerebral cortex. J Neurol Sci.
1992;108:80–87.
15. Coyle JT, Schwarcz R. Lesion of striatal neurones with kainic acid
880 provides a model for Huntington’s chorea. Nature.
1976;263:244–246.
16. Beal MF, Kowall NW, Ellison DW, et al. Replication of the neuro-
chemical characteristics of Huntington’s disease by quinolinic acid.
Nature. 1986;321:168–171.
885 •• The work of Beal and collegues presents the QUIN- model of HD.
17. Stone TW, Perkins MN. Quinolinic acid: a potent endogenous exci-
tant at amino acid receptors in CNS. Eur J Pharmacol.
1981;72:411–412.
18. Young AB, Greenamyre JT, Hollingsworth Z, et al. NMDA receptor
890 losses in putamen from patients with Huntington’s disease.
Science. 1988;241:981–983.
19. Albin RL, Young AB, Penney JB, et al. Abnormalities of striatal
projection neurons and N-methyl-D-aspartate receptors in pre-
symptomatic Huntington’s disease. N Engl J Med.
895 1990;322:1293–1298.
20. Stoy N, Mackay GM, Forrest CM, et al. Tryptophan metabolism and
oxidative stress in patients with Huntington’s disease.
J Neurochem. 2005;93:611–623.
•• In this work, Stoy and collegues indicate that HD is accompa-
900 nied by elevated inflammatory markers – not only in the CNS,
but in the periphery as well.
21. Zádori D, Geisz A, Vámos E, et al. Valproate ameliorates the survival
and the motor performance in a transgenic mouse model of
Huntington’s disease. Pharmacol Biochem Behav. 2009;94:148–153.
905 22. Stahl WL, Swanson PD. Biochemical abnormalities in Huntington’s
chorea brains. Neurology. 1974;24:813–819.
23. Greene JG, Porter RHP, Eller RV, et al. Inhibition of succinate dehy-
drogenase by malonic acid produces an “excitotoxic” lesion in rat
striatum. J Neurochem. 1993;61:1151–1154.
910 24. Jenkins BG, Koroshetz WJ, Beal MF, et al. Evidence for im�pairment
of energy metabolism in vivo in Huntington’s disease using loca-
lized 1H NMR spectroscopy. Neurology. 1993;43:2689–2695.
25. Koroshetz WJ, Jenkins BG, Rosen BR, et al. Energy metabolism
defects in Huntington’s disease and effects of coenzyme Q10.
915 Ann Neurol. 1997;41:160–165.
26. Schilling G, Coonfield ML, Ross CA, et al. Coenzyme Q10 and
remacemide hydrochloride ameliorate motor deficits in
a Huntington’s disease transgenic mouse model. Neurosci Lett.
2001;315:149–153.
920 27. Ferrante RJ, Andreassen OA, Dedeoglu A, et al. Therapeutic effects
of Coenzyme Q10 and remacemide in transgenic mouse models of
Huntington’s disease. J Neurosci. 2002;22:1592–1599.
28. Group THS. A randomized, placebo-controlled trial of coenzyme
Q10 and remacemide in Huntington’s disease. Neurology.
9252001;57:397–404.
29. Wyttenbach A, Sauvageot O, Carmichael J, et al. Heat shock protein
27 prevents cellular polyglutamine toxicity and suppresses the
increase of reactive oxygen species caused by huntingtin. Hum
Mol Genet. 2002;11:1137–1151.
93030. Tabrizi SJ, Cleeter MWJ, Xuereb J, et al. Biochemical abnormalities
and excitotoxicity in Huntington’s disease brain. Ann Neurol.
1999;45:25–32.
31. Sapp E, Kegel KB, Aronin N, et al. Early and progressive accumula-
tion of reactive microglia in the Huntington disease brain.
935J Neuropathol Exp Neurol. 2001;60:161–172.
32. Simmons DA, Casale M, Alcon B, et al. Ferritin accumulation in
dystrophic microglia is an early event in the development of
Huntington’s disease. Glia. 2007;55:1074–1084.
33. Singhrao SK, Neal JW, Morgan BP, et al. Increased complement
940biosynthesis by microglia and complement activation on neurons
in Huntington’s disease. Exp Neurol. 1999;159:362–376.
34. Forrest CM, Mackay GM, Stoy N, et al. Blood levels of kynurenines,
interleukin-23 and soluble human leucocyte antigen-G at different
stages of Huntington’s disease. J Neurochem. 2010;112:112–122.
94535. Paulsen JS, Nehl C, Hoth KF, et al. Depression and stages of
Huntington’s disease. J Neuropsychiatry Clin Neurosci.
2005;17:496–502.
36. Leklem JE. Quantitative aspects of tryptophan metabolism in humans
and other species: a review. Am J Clin Nutr. 1971;24:659–672.
95037. Mándi Y, Vécsei L. The kynurenine system and immunoregulation.
J Neural Transm. 2012;119:197–209.
38. Pardridge WM. Blood-brain barrier carrier-mediated transport and
brain metabolism of amino acids. Neurochem Res. 1998;23:635–644.
39. Wolf H. The effect of hormones and vitamin B6 on urinary excretion
955of metabolites of the kynurenine pathway. Scand J Clin Lab Suppl.
1974;136:1–186.
40. Han Q, Cai T, Tagle DA, et al. Structure, expression, and function of
kynurenine aminotransferases in human and rodent brains. Cell
Mol Life Sci. 2010;67:353–368.
96041. Okuno E, Nakamura M, Schwarcz R. Two kynurenine aminotrans-
ferases in human brain. Brain Res. 1991;542:307–312.
42. Elmslie KS, Yoshikami D. Effects of kynurenate on root potentials
evoked by synaptic activity and amino acids in the frog spinal cord.
Brain Res. 1985;330:265–272.
96543. Albuquerque EX, Schwarcz R. Kynurenic acid as an antagonist of
α7�nicotinic Acetylcholine receptors in the brain: facts and chal-
lenges. Biochem Pharmacol. 2013;85:1027–1032.
44. Marchi M, Risso F, Viola C, et al. Direct evidence that
release-stimulating alpha�-7nicotinic cholinergic receptors are loca-
970lized on human and rat brain glutamatergic axon terminals.
J Neurochem. 2002;80:1071–1078.
45. Mok MHS, Fricker A-C, Weil A, et al. Electrophysiological character-
isation of the actions of kynurenic acid at ligand-gated ion
channels. Neuropharmacology. 2009;57:242–249.
97546. Dobelis P, Staley KJ, Cooper DC. Lack of modulation of nicotinic
acetylcholine alpha-7 receptor currents by kynurenic acid in adult
hippocampal interneurons. PLoS. 2012;7:1–6.
47. Lugo-Huitrón R, Blanco-Ayala T, Ugalde-Muñiz P, et al.
Neurotoxicology and teratology on the antioxidant properties of
980kynurenic acid: free radical scavenging activity and inhibition of
oxidative stress. Neurotoxicol Teratol. 2011;33:538–547.
48. Shoki O, Nobuyoshi N, Hiroshi S, et al. 3-hydroxykynurenine, an
endogenous oxidative stress generator, causes neuronal cell death
with apoptotic features and region selectivity. J Neurochem
985[Internet]. 1998;70:299–307.
49. Zhuravlev AV, Zakharov GA, Shchegolev BF, et al. Antioxidant
properties of kynurenines: density functional theory calculations.
PLOS Compotational Biol [Internet]. 2016;1–31. DOI:10.1371/jour-
nal.pcbi.1005213
EXPERT OPINION ON THERAPEUTIC TARGETS 11
990 50. Guillemin GJ. Quinolinic acid, the inescapable neurotoxin. FEBS J.
2012;279:1356–1365.
51. Vecsei L, Szalardy L, Fulop F, et al. Kynurenines in the CNS: recent
advances and new questions. Nat Rev Drug Discov. 2012 [cited Dec
15];12:64–82.
995 52. Schwarcz R, Pellicciari R. Manipulation of brain kynurenines: glial
targets, neuronal effects, and clinical opportunities. J Pharmacol
Exp Ther. 2002;303:1–10.
• This article reveals the link between mutant HTT and the KP.
53. Giorgini F, Guidetti P, Nguyen Q, et al. A genomic screen in yeast
1000 implicates kynurenine 3- monooxygenase as a therapeutic target
for Huntington’s disease. Nat Genet. 2005;37:526–531.
54. Beal MF, Matson WR, Swartz KJ, et al. Kynurenine pathway mea-
surements in Huntington’s disease striatum: evidence for reduced
formation of kynurenic acid. J Neurochem. 1990;55:1327–1339.
1005 55. Jauch D, Urbanska EM, Guidetti P, et al. Dysfunction of brain
kynurenic acid metabolism in Huntington’s disease: focus on
kynurenine aminotransferases. J Neurol Sci. 1995;130:39–47.
56. Heyes MP, Saito K, Crowley JS, et al. Quinolinic acid and kynurenine
pathway metabolism in inflammatory and non-inflammatory neu-
1010 rological disease. Brain. 1992;115:1249–1273.
57. Schwarcz R, Okuno E, White RJ, et al. 3-Hydroxyanthranilate oxyge-
nase activity is increased in the brains of Huntington disease
victims. Proc Natl Acad Sci USA 1988;85:4079–4081.
58. Guillemin GJ, Kerr SJ, Smythe GA, et al. Kynurenine pathway meta-
1015 bolism in human astrocytes: a paradox for neuronal protection.
J Neurochem. 2001;78:842–853.
59. Reynolds GP, Pearson SJ, Halket J, et al. Brain quinolinic acid in
Huntington’s disease. J Neurochem. 1988;50:1959–1960.
60. Guidetti P, Luthi-Carter RE, Augood SJ, et al. Neostriatal and cortical
1020 quinolinate levels are increased in early grade Huntington’s dis-
ease. Neurobiol Dis. 2004;17:455–461.
61. Guidetti P, Bates GP, Graham RK, et al. Elevated brain
3-hydroxykynurenine and quinolinate levels in Huntington disease
mice. Neurob. 2006;23:190–197.
1025 62. Pearson SJ, Reynolds GP. Increased brain concentrations of
a neurotoxin, 3-hydroxykynurenine, in Huntington’s disease.
Neurosci Lett. 1992;144:199–201.
63. Guidetti P, Reddy PH, Tagle DA, et al. Early kynurenergic impair-
ment in Huntington’s disease and in a transgenic animal model.
1030 Neurosci Lett. 2000;283:233–235.
64. Sathyasaikumar KV, Stachowski EK, Amoria L, et al. Dysfunctional
kynurenine pathway metabolism in the R6/2 mouse model of
Huntington’s disease. J Neuro. 2010;113:1416–1425.
65. Gál EM, Sherman AD. Synthesis and metabolism of L-kynurenine in
1035 rat brain. J Neurochem. 1978;30:607–613.
66. Vamos E, Pardutz A, Klivenyi P, et al. The role of kynurenines in
disorders of the central nervous system: possibilities for
neuroprotection. J Neurol Sci. 2009;283:21–27.
67. Santamaria A, Rios C, Solís-Hernández F, et al. Systemic DL-kynurenine
1040 and probenecid pretreatment attenuates quinolinic acid-induced
neurotoxicity in rats. Neuropharmacology. 1996;35:23–28.
68. Guidetti P, Wu H, Schwarcz R. In situ produced
7-chlorokynurenate provides protection against quinolinate- and
malonate-induced neurotoxicity in the rat striatum. Exp Neurol.
1045 2000;163:123–130.
69. Zádori D, Nyiri G, Szőnyi A, et al. Neuroprotective effects of a novel
kynurenic acid analogue in a transgenic mouse model of
Huntington’s disease. J Neural Transm. 2011;118:865–875.
70. Toledo-Sherman LM, Prime ME, Mrzljak L, et al. Development of
1050 a series of aryl pyrimidine kynurenine monooxygenase inhibitors as
potential therapeutic agents for the treatment of Huntingtons
disease. J Med Chem. 2015;58:1159–1183.
71. Harris CA, Miranda AF, Tanguay JJ, et al. Modulation of striatal
quinolinate neurotoxicity by elevation of endogenous brain
1055 kynurenic acid. Br J Pharmacol. 1998;124:391–399.
72. Zwilling D, Huang S, Sathyasaikumar KV, et al. Kynurenine
3-monooxygenase inhibition in blood ameliorates
neurodegeneration. Cell. 2012;145:863–874.
73. Okamoto S, Pouladi MA, Talantova M, et al. Balance between
1060synaptic versus extrasynaptic NMDA receptor activity influences
inclusions and neurotoxicity of mutant huntingtin. Nat Med.
2010;15:1407–1413.
74. Szalardy L, Zadori D, Toldi J, et al. Manipulating kynurenic acid
levels in the brain – on the edge between neuroprotection
1065and cognitive dysfunction. Curr Top Med Chem.
2012;12:1797–1806.
75. Ball HJ, Sanchez-Perez A, Weiser S, et al. Characterization of an
indoleamine 2,3-dioxygenase-like protein found in humans and
mice. Gene. 2007;396:203–213.
107076. Metz R, DuHadaway JB, Kamasani U, et al. Novel tryptophan cata-
bolic enzyme IDO2 is the preferred biochemical target of the
antitumor indoleamine 2,3-dioxygenase inhibitory compound
D-1-methyl-tryptophan. Cancer Res. 2007;67:7082–7087.
77. Yuasa HJ, Ball HJ. Indoleamine 2,3-dioxygenases with very low
1075catalytic activity are well conserved across kingdoms: IDOs of
basidiomycota. Fungal Genet Biol [Internet]. 2013;56:98–106.
78. Ball HJ, Yuasa HJ, Austin CJD, et al. Indoleamine 2,3-dioxygenase-2;
a new enzyme in the kynurenine pathway. Int J Biochem Cell Biol.
2009;41:467–471.
108079. Yuasa HJ, Ball HJ, Fern Y, et al. Characterization and evolution of
vertebrate indoleamine 2,3-dioxygenases IDOs from monotremes
and marsupials. Comp Biochem Physiol Part B. 2009;153:137–144.
80. van Baren N, Van den Eynde B. Tryptophan-degrading enzymes in
tumoral immune resistance. Front Immunol. 2015;6:1–9.
108581. Smith AK, Simon J, Gustafson E, et al. Association of
a polymorphism in the indoleamine-2,3- dioxygenase gene and
interferon-α-induced depression in patients with chronic hepatitis
C. Mol Psychiatry [Internet]. 2012;17:781–789. Available from:
http://www.nature.com/mp/journal/v17/n8/abs/mp201167a.html
109082. Munn D, Zhou M, Attwood J, et al. Prevention of allogeneic fetal
rejection by tryptophan catabolism. Science [Internet].
1998;281:1191–1193. Available from: http://www.ncbi.nlm.nih.gov/
pubmed/9712583
83. Badawy AA-B, Namboodiri AMA, Moffett JR. The end of the road for
1095the tryptophan depletion concept in pregnancy and infection. Clin
Sci. 2016;130:1327–1333.
84. Yeung AWS, Terentis AC, King NJC, et al. Role of indoleamine
2,3-dioxygenase in health and disease. Clin Sci. 2015;129:601–672.
85. Baban B, Chandler P, Sharma M, et al. IDO activates regulatory
1100T cells and blocks their conversion into TH17-like T cells.
J Immunol. 2009;183:2475–2483.
86. Sharma MD, Huang L, Choi J-H, et al. An inherently bi-functional
subset of FOxp3+ T helper cells is controlled by the transcription
factor Eos. Immunitiy. 2013;38:998–1012.
110587. Munn DH, Sharma MD, Baban B, et al. GCN2 kinase in T cells
mediates proliferative arrest and anergy induction in response to
indoleamine 2,3-dioxygenase. Immunity. 2005;22:633–642.
88. Terness P, Bauer TM, Röse L, et al. Inhibition of allogeneic T cell
proliferation by indoleamine 2,3-�dioxygenase – expressing dendri-
1110tic cells: mediation of suppression by tryptophan metabolites. J Exp
Med. 2002;196:447–457.
89. Scott GN, DuHadaway J, Pigott E, et al. The immunoregulatory
enzyme IDO paradoxically drives B cell-mediated autoimmunity.
J Immunol. 2010;182:7509–7517.
111590. Liu H, Huang L, Bradley J, et al. GCN2-dependent metabolic stress is
essential for endotoxemic cytokine induction and pathology. Mol
Cell Biol. 2014;34:428–438.
91. Wang X-F, Wang H-S, Wang H, et al. The role of indoleamine
2,3-dioxygenase (IDO) in immune tolerance: focus on macrophage
1120polarization of THP-1 cells. Cell Immunol. 2014;289:42–48.
92. El-Zaatari M, Chang Y, Zhang M, et al. Tryptophan catabolism
restricts IFN-γ−expressing neutrophils and clostridium difficile
immunopathology. J Immunol. 2014;193:807–816.
93. Boasso A, Herbeuval J-P, Hardy AW, et al. HIV inhibits CD4+ T-cell
1125proliferation by inducing indoleamine 2,3-dioxygenase in plasma-
cytoid dendritic cells. Immunobilologyology. 2007;109:3351–3360.
12 F. A. BOROS ET AL.
94. Gaelings L, Söderholm S, Bugai A, et al. Regulation of kynurenine
biosynthesis during influenza virus infection. FEBS J.
2017;284:222–236.
1130 95. Zhou L, Chen H, Wen Q, et al. Indoleamine 2,3-dioxygenase expres-
sion in human inflammatory bowel disease. Eur J Gastroenterol
Hepatol. 2012;24:695–701.
96. Kwidzinski E, Aktas O, Richter D, et al. Indolamine 2,3-dioxygenase
is expressed in the CNS and down-regulates autoimmune
1135 inflammation. FASEB J. 2005;19:1–19.
• The work of Kwidzinski et al. points out the dangers of IDO
inhibition in a mouse model of multiple sclerosis.
97. Munn DH. Indoleamine 2,3-dioxygenase, tumor-induced tolerance
and counter-regulation. Curr Opin Immunol. 2006;18:220–225.
1140 98. Widner B, Leblhuber F, Fuchs D. Increased neopterin production
and tryptophan degradation in advanced Parkinson’s disease.
J Neural Transm. 2002;109:181–189.
99. Guillemin GJ, Brew BJ, Noonan CE, et al. Indoleamine 2,3 dioxygen-
ase and quinolinic acid immunoreactivity in Alzheimer’s disease
1145 hippocampus. Neuropathol Appl Neurobiol. 2005;31:395–404.
100. Campesan S, Green EW, Breda C, et al. The kynurenine pathway
modulates neurodegeneration in a drosophila model of
Huntington’s disease. Curr Biol. 2011;21:961–966.
•• The findings of Campesan et al. show that genetic inhibiton of
1150 the Tdo2 enzyme (which can be considered an analogue of
human IDO) in a Drosophila melanogaster HD model is protec-
tive against mutant Htt protein neurotoxicity.
101. Mazarei G, Budac DP, Lu G, et al. The absence of indoleamine
2,3-dioxygenase expression protects against NMDA
1155 receptor-mediated excitotoxicity in mouse brain. Exp Neurol J.
2013;249:144–148.
•• Mazarei and collegues showed that the lack of Ido gene in
a mouse model resulted in decreased NMDA receptor-
mediated toxicity.
1160 102. Guidetti P, Schwarcz R. 3-Hydroxykynurenine potentiates quinoli-
nate but not NMDA toxicity in the rat striatum. Eur J Neuro.
1999;11:3857–3863.
103. Stone TW, Forrest CM, Stoy N, et al. Involvement of kynurenines in
Huntington’s disease and stroke-induced brain damage. J Neu.
11652012;119:261–274.
104. Wurster CD, Ludolph AC. Antisense oligonucleotides in neurologi-
cal disorders. Ther Adv Neurol Disord. 2018;11:1–19.
105. Tabrizi S, Leavitt B, Kordasiewicz H, et al. Effects of IONIS-HTTRx in
patients with early Huntington’s disease, results of the first HTT-
1170lowering drug trial (CT.002). Neurology. 2018;90�:(15 Supplement).
AQ4
�
106. Maes M, Meltzer HY, Bosmans E, et al. Relationships between lower
plasma L-tryptophan levels and immune-inflammatory variables in
depression. Psychiatry Res. 1993;49:151–165.
• The work of Maes and collegues supports the notion that depres-
1175sive symproms are amerliorated via IDO inhibition, as peripherial
inflammation (an inducer of IDO expression) was shown to con-
tribute to the appearance of depressive symptoms.
107. Wichers MC, Maes M. The role of indoleamine 2,3-dioxygenase
(IDO) in the pathophysiology of interferon-α-induced depression.
1180J Psychiatry Neurosci. 2004;29:11–17.
108. Yang G, Lu X, Yuan L. Biochimica et biophysica acta LncRNA: a link
between RNA and cancer. BBA Gene Regul Mech [Internet].
2014;1839:1097–1109.
109. Jasperson LK, Bucher C, Panoskaltsis-Mortari A, et al. Indoleamine
11852,3-dioxygenase is a critical regulator of acute graft-versus-host
disease lethality. Blood. 2008;111:3257–3266.
110. Reniers J, Meinguet C, Moineaux L, et al. Synthesis and inhibition
study of monoamine oxidase, indoleamine 2,3-dioxygenase and
tryptophan 2,3-dioxygenase by 3,8-substituted 5H-indeno[1,2-c]
1190pyridazin-5-one derivatives. Eur J Med Chem. 2011;46:6104–6111.
111. Jiang T, Sun Y, Yin Z, et al. Research progress of indoleamine
2,3-dioxygenase inhibitors. Future Med Chem. 2015;7:185–201.
• This review of developed IDO inhibitors, of which two have
already reached clinical trials in cancer therapy, strenghtens
1195the notion of IDO inhibition as a therapeutic approach.
EXPERT OPINION ON THERAPEUTIC TARGETS 13
